Sun Pharmaceuticals will sell the rights to one generic drug as part of its purchase of competitor Ranbaxy Laboratories, U.S. antitrust regulators said Friday. The Federal Trade Commission said the companies will sell Ranbaxy's interests in generic minocycline, an antibiotic used to treat several types of infections.
Just over a week after saying it would sell its heartworm treatment for dogs at the request of...
The Federal Trade Commission is requiring the sale of Eli Lilly's Sentinel heartworm products...
Federal regulators announced Thursday they were suing Gerber, the well-known baby food maker, for claiming that its Good Start Gentle formula can prevent or reduce allergies in children.
If you purchased caffeine-infused underwear because of promises it will make you thinner, federal regulators say you were hoodwinked — but at least you can get your money back.
The FTC says AbbVie and its partner and Besins Healthcare filed baseless patent infringement lawsuits against Teva Pharmaceutical Industries Ltd. and Perrigo Co. to delay the approval and sale of less-expensive generic versions of the drug.
CNN reports on the FTC's crackdown on weight-loss products for deceptive advertising.
Actavis announced that federal regulators have requested additional information related to its planned acquisition of fellow drugmaker Warner Chilcott PLC. The $8.5 billion all-stock deal originally announced in May would create the third-biggest specialty pharmaceutical company in the U.S. market.
Hedge fund manager William Ackman is applauding a consumer group's push for the Federal Trade Commission to investigate whether Herbalife is a pyramid scheme. The National Consumers League said that it wants the FTC to investigate the claims against Herbalife as well as the vitamin and supplement products company's responses.
FTC Study: In FY 2012, Branded Drug Firms Significantly Increased the Use of Potential Pay-for-Delay Settlements to Keep Generic Competitors off the MarketJanuary 17, 2013 9:21 am | by Federal Trade Commission | News | Comments
Record Number of Agreements Cover 31 Different Products, With Combined Annual U.S. Sales of More Than $8.3 Billion
The Federal Trade Commission has upheld a judge's earlier decision that POM Wonderful made deceptive claims about the health benefits of its products.
FTC Approves Final Order Settling Charges That Watson Pharmaceuticals, Inc.'s Acquisition of Actavis Inc. Would Have Been AnticompetitiveDecember 14, 2012 6:21 am | by Federal Trade Commission | News | Comments
Following a public comment period, the Federal Trade Commission has approved a final order settling charges that Watson Pharmaceuticals, Inc.?s proposed acquisition of Actavis Inc. would have been anticompetitive in the markets for 21 current and future generic drugs used to treat a wide...
FTC Staff Opinion: The Methodist Hospital System May Sell Discounted Shortage Drugs to Baytown EMS as an Emergency Humanitarian Gesture; FTC Approves Final Order Settling Char...November 30, 2012 7:20 am | by Federal Trade Commission | News | Comments
In a letter issued today, the staff of the Federal Trade Commission advised The Methodist Hospital System that its proposal to resell pharmaceuticals it purchased at a discount to Baytown EMS is a permissible emergency humanitarian gesture. Following a public comment period, the Federal...
FTC Files Amicus Brief Explaining That Pharmaceutical "Product Hopping" Can Be the Basis for an Antitrust LawsuitNovember 27, 2012 7:21 am | by Federal Trade Commission | News | Comments
The Federal Trade Commission filed an amicus brief before the U.S. District Court for the Eastern District of Pennsylvania explaining that minor, non-therapeutic changes to a branded pharmaceutical product that harm generic competition can constitute exclusionary conduct that violates...
To Protect Competition, Companies Agree to Sell Rights and Assets to 18 Drugs to Sandoz and Par, Relinquish Manufacturing and Marketing Rights for Three Other Drugs
FTC Submits Amicus Brief Explaining that Drug Companies Use ?No-Authorized Generic? Agreements to Delay Generic CompetitionOctober 9, 2012 6:21 am | by Federal Trade Commission | News | Comments
The Federal Trade Commission filed an amicus brief in the U.S. District Court for the District of New Jersey stating that an agreement by a branded drug company not to launch an authorized generic (AG) drug ?provides a convenient method for branded drug firms to pay generic patent...
Solicitor General of the United States Files Petition on Behalf of the Agency
Unsupported Weight-Loss Claims Violated Previous Order, Agency Alleges
The FTC will provide refunds to nearly 13,000 consumers who paid significantly more for their drugs than they expected based on allegedly deceptive pricing claims made by CVS Caremark.
FTC Files Amicus Brief Explaining That "No-AG" Agreements Are Used by Drug Companies to Delay Generic CompetitionAugust 13, 2012 8:20 am | by Federal Trade Commission | News | Comments
The Federal Trade Commission filed an amicus brief before the U.S. District Court for the District of New Jersey explaining that an agreement by a branded company not to launch an authorized generic (AG) drug is a ?convenient method? for branded drug firms to pay generic patent...
FTC Staff Issues Advisory Opinion Regarding Generic Pharmaceutical Association's Proposed Initiative to Address Drug ShortagesAugust 8, 2012 11:20 am | by Federal Trade Commission | News | Comments
Program's Numerous Safeguards Make It Unlikely to Harm Competition
Statement by Federal Trade Commission Chairman Jon Leibowitz on the U.S. Court of Appeals for the Third Circuit Ruling in the K-Dur 20 MatterJuly 16, 2012 9:20 am | by Federal Trade Commission | News | Comments
Federal Trade Commission Chairman Jon Leibowitz issued the following statement regarding a key ruling issued today by a panel of the U.S. Court of Appeals for the Third Circuit regarding the legality of patent settlements between branded and generic manufacturers of the high blood...
Settlement Order Protects Competition in the Markets for Skin Care Gels and Cream
FTC Approves Amended Final Order Settling Charges that Teva's Proposed Acquisition of Cephalon was Anticompetitive in Markets for Several Generic DrugsJuly 3, 2012 7:21 am | by Federal Trade Commission | News | Comments
Following a public comment period, the Federal Trade Commission has approved an amended final order settling charges that Teva Pharmaceutical Industries, Ltd.'s proposed acquisition of rival Cephalon, Inc. would have been anticompetitive in the markets for several current and future generic drugs.
FTC Issues Modified Final Order Settling Charges that Perrigo's Acquisition of Paddock Laboratories Was Anticompetitive in Market for Generic PharmaceuticalsJune 26, 2012 9:21 am | by Federal Trade Commission | News | Comments
Following a public comment period, the Federal Trade Commission has issued a modified final order settling charges that Perrigo Company's $540 million acquisition of Paddock Laboratories, Inc., as proposed, was anticompetitive and would have reduced the number of manufacturers for four...
Following a public comment period, the FTC has accepted as final an order with CVS Caremark settling charges that it misrepresented the prices of certain Medicare Part D prescription drugs, including drugs used to treat breast cancer symptoms and epilepsy, at CVS and Walgreens pharmacies.
Federal Trade Commission Chairman Jon Leibowitz released the agency?s 2012 Annual Highlights today at the spring meeting of the American Bar Association?s Section of Antitrust Law in Washington, DC, recognizing the agency?s continued efforts to protect consumers and promote competition.
The Federal Trade Commission testified today before Congress about proposed legislation that would exempt independent pharmacies from the antitrust laws, saying that such an exemption is likely to reduce competition and innovation, and ultimately increase prices for health care consumers...
- Page 1